Zurich, Switzerland – May 22, 2025 MaxWell Biosystems AG is advancing its global go-to-market strategy with the establishment of a dedicated EMEA regional team, expanding its presence and partnerships across Europe, the Middle East, and Africa. This move is part of the company’s global commercial evolution as demand continues to rise for its high-resolution electrophysiology platforms.

Meet the MaxWell Biosystems EMEA Team

The newly formed EMEA regional team unites sales, business development, account management, and customer success roles to accelerate adoption, strengthen collaborations, and better serve the evolving needs of users in research and drug discovery across the region.

“Regional empowerment is a key step in scaling MaxWell Biosystems’ presence and performance across EMEA,” said Marie Obien, CCO of MaxWell Biosystems. “With a focused team in place, we are engaging more closely with our users, expanding our customer base, and executing with greater precision across key biopharma and academic markets in the region.”

Giulio Zorzi, Head of EMEA

EMEA is one of the regions established under this model, with other expansions ongoing in Asia-Pacific and the Americas. Leading the EMEA team is Giulio Zorzi, a seasoned commercial leader returning to MaxWell Biosystems with a strong track record of translating scientific potential into customer success

“We’re proud to launch this new MaxWell era with a passionate EMEA team,” said Giulio Zorzi. “We’re at the forefront of a transformation in functional cell analysis, and I’m excited to lead our commercial expansion across EMEA. My focus will be on forging strategic partnerships, scaling adoption in the region, and supporting our users in accelerating their research and innovation.”

The regionalization initiative reinforces MaxWell Biosystems’ commitment to scalable, customer-centric growth and broader scientific impact—advancing its mission to empower breakthroughs in neuroscience and drug discovery through next-generation high-content electrophysiology.

Contact

Dr. Marie Obien
Chief Commercial Officer
Phone +41 44 244 24 19
marie.obien@mxwbio.com

About MaxWell Biosystems

MaxWell Biosystems AG develops high-content electrophysiology platforms that accelerate drug discovery and advance the understanding of complex neuronal systems. Established in 2016 as a spin-off from ETH Zurich, the company is a leading expert in high-density microelectrode array (HD-MEA) technology, offering both proprietary hardware and software solutions. Its first product, MaxOne, enables detailed single-well analysis of cellular activity at network, cellular, and subcellular levels. The subsequent release of MaxTwo, a multi-well HD-MEA platform, significantly increases assay throughput with 6- and 24-well formats, addressing the needs of pharmaceutical companies, biotechnology firms, and contract research organizations. By equipping scientists with precise, scalable tools for in vitro functional analysis, MaxWell Biosystems empowers breakthroughs in neuroscience, disease modeling, and translational research.

Every cell has a story to tell.

Download Press Release

View Fullscreen